MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
6.81
+0.27
+4.13%
Opening 12:52 08/17 EDT
OPEN
6.70
PREV CLOSE
6.54
HIGH
7.51
LOW
6.54
VOLUME
95.94K
TURNOVER
--
52 WEEK HIGH
17.94
52 WEEK LOW
3.350
MARKET CAP
149.04M
P/E (TTM)
-2.1238
1D
5D
1M
3M
1Y
5Y
1D
Rosen Law Firm Urges Aardvark Therapeutics, Inc. (NASDAQ: AARD) Stockholders to Contact the Firm for Information About Their Rights
Barchart · 6h ago
Weekly Report: what happened at AARD last week (0810-0814)?
Weekly Report · 6h ago
We Think Aardvark Therapeutics (NASDAQ:AARD) Needs To Drive Business Growth Carefully
Simply Wall St · 1d ago
AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
Barchart · 1d ago
Stockholder Alert: Robbins LLP Informs Investors of the Aardvark Therapeutics, Inc. (UWM) Class Action
Barchart · 2d ago
Analysts Offer Insights on NA Companies: Nakamoto Inc (NAKA) and Aardvark Therapeutics, Inc. (AARD)
TipRanks · 3d ago
Stifel Nicolaus Keeps Their Hold Rating on Aardvark Therapeutics, Inc. (AARD)
TipRanks · 4d ago
Regulatory Overhang and Funding Needs Keep Aardvark’s ARD-101 Outlook Balanced, Justifying Neutral Rating
TipRanks · 4d ago
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.